Akzo N.v.

Akzona Incorporated

Thomas Sleigh

David S Savage

Ian C Carlyle

John K Clark

Duncan R Rae

Filippus J Zeelen

James Redpath

Colin L Hewett

Robert Taylor

Alan W Muir

Monoquaternary 2,16-bispiperidinylandrostane neuromuscular blocking derivatives having the formula: ##STR1## wherein R.sub.1 is ethyl;

Monoquaternary 2,16-bispiperidinylandrostane derivatives

Compounds having the formula: ##STR1## wherein R.sub.1 is H or an optionally substituted acyl group having 1-12 carbon atoms,

Novel 2.beta.-morpholino-androstane derivatives

2.beta.,16.beta.-diamino-3.alpha.,17.alpha.-oxygenated androstanes having one quaternized group, process for the preparation of these compounds and pharmaceutical compositions comprising such compounds as the active ingredient. The aforementioned compounds are favourable neuro-muscular blocking agents.

Novel 2.beta.,16.beta.-diamino-androstanes

The present invention relates to novel biologically active tricyclic compounds, of the general formula I: ##STR1## and salts thereof, in which R.sub.1 represents hydrogen, alkyl of 1-6 carbon atoms, an optionally substituted aralkyl group or an acyl group,

Biologically active tricyclic compounds and pharmaceutical compositions

The invention concerns novel anti-arrhythmic amino-alcohol derivatives, characterized by the general formula (1) ##STR1## or pharmaceutically acceptable salts thereof, wherein R.sub.1, R.sub.2 and R.sub.3 each independently represent hydrogen, alkyl having 1-6 carbon atoms, alkoxy having 1-6 carbon atoms, acyloxy having 1-6 carbon atoms, hydroxy, halogen or optionally alkyl-substituted amino;

Anti-arrhythmic amino-alcohols

This invention relates to novel mono- and bisquaternary ammonium derivatives of 5.alpha.-androstanes having the formula: ##STR1## wherein: R.sub.1 =H or alkyl (1-4 C);

Mono- and bisquaternary ammonium derivatives of

New and pharmacologically useful 17-amino-16-hydroxy-steroids of the androstane and oestrane series are disclosed having the formula I: ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, wherein:

Novel 17-amino-16-hydroxy steroids of the androstane and oestrane series

New and pharmacologically useful pharmaceutically acceptable acid addition salts are disclosed for the 16.beta.-monoquaternary ammonium derivatives of either the 2.beta., 16.beta.-bis-piperdino-3.alpha., 17.beta.-dihydroxy-5.alpha.-androstane 3.alpha., 17.beta.-di-lower aliphatic esters or the 2.beta., 16.beta.-bis-piperidino-3.alpha.-hydroxy-5.alpha.-androstane-3.alpha.-lowe r aliphatic esters, which salts are surprisingly relatively stable in aqueous solutions, so that they provide stable aqueous injection preparations.

Method of manufacture and use of improved 2.beta., 16.beta.-piperidino

New and pharmacologically useful pharmaceutically acceptable acid addition salts are disclosed for the 16.beta.-mono-quaternary ammonium derivatives of either the 2.beta., 16.beta.-bis-piperdino-3-.alpha., 17.beta.-dihydroxy-5.alpha.-androstane 3.alpha., 17.beta.-di-lower aliphatic esters of the 2.beta., 16.beta.-bis-piperidino-3.alpha.-hydroxy-5.alpha.-androstane-3.alpha.-lowe r aliphatic esters, which salts are surprisingly relatively stable in aqueous solutions, so that they provide stable aqueous injection preparations.

2.beta., 16.beta.-bis-piperidino-androstanes

The present invention relates to novel benzo(b) bicyclo[3.3.1]nones of the general formula I: ##STR1## and a salt or nitrogen oxide thereof, in which R.sub.1 and R.sub.2 stand for hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 1-6 carbon atoms, an optionally substituted aralkyl group or an acyl group or

Growing community of inventors

Wishaw, United Kingdom

Thomas Sleigh